PARP Pioneers: Using BRCA1/2 Mutation-targeted Inhibition to Revolutionize Breast Cancer Treatment.

Area of Science:

• Oncology
• Genetics
• Molecular Biology

Background:

• Breast cancer is a leading global malignancy, often driven by BRCA1/BRCA2 gene mutations.
• BRCA genes are crucial for DNA repair via homologous recombination (HRR).
• Poly (ADP-ribose) polymerases (PARP) are key enzymes in DNA damage repair.

Purpose of the Study:

• To review the role of oral PARP inhibitors (PARPi) in breast cancer treatment.
• To update on the therapeutic advancements and management strategies using PARPi.

Main Methods:

• Review of current literature on PARP inhibitors in breast cancer.
• Analysis of clinical data regarding PARPi efficacy and safety.

Main Results:

• PARP inhibitors are effective as monotherapies for HER2-negative, BRCA-mutated breast cancer.
• PARPi demonstrate varying potency in DNA trapping and cytotoxicity, influencing safety and efficacy.
• PARPi have shown potential benefits across diverse breast cancer subtypes.

Conclusions:

• PARP inhibitors represent a significant advancement in breast cancer therapy.
• Targeting DNA repair mechanisms with PARPi offers a promising strategy for managing breast cancer.
• Further research into PARPi mechanisms and applications is warranted.